Real Money authors - Stephen Guilfoyle

Stephen Guilfoyle

Stephen "Sarge" Guilfoyle is the founder and President of Sarge986 LLC, a family run trading operation. An NYSE floor trader for over 30 years, Guilfoyle has served as the Chief Market Economist for Stuart Frankel & Co., the U.S. Economist for Meridian Equity Partners, and as a Vice President in Block Trading and Investment Banking with Credit Suisse over the years. Guilfoyle earned his nickname serving as an actual sergeant in reserve components of the US Marine Corps, and US Army while simultaneously working on Wall Street.
Email Stephen Guilfoyle

Recent Articles By The Author

Is It Too Late to Get Into Nvidia? Here's My Trade Idea

Assuming that enough of you are either long NVDA, or at least have an interest in the name, let's take a look under the hood, and make a more determined decision here.

G-20 Trades and OPEC Cuts: Market Recon

Equity index futures were rising Monday morning on positive trade news.

Halfway Through 2019, Consider These 26 Stocks

Let's dissect what we are looking at, slow it down, take it apart, put it back together, and then kick it twice for good measure.

June Rotations and Why I Like Apple on Jony Ive's Departure: Market Recon

The risk is that the chief design officer's departure will cause technical issues in Apple's chart.

Boeing Stock Is Losing Altitude Here, But Don't Hop on for the Ride

The risk/reward ratio doesn't look good for retail investors.

Trump-Xi Face Off, Potential EU Land Mines and a Caterpillar Play: Market Recon

The G-20 Summit in Japan could hold more intrigue than just the planned meeting between President Trump and Xi.

Do Micron's Numbers Scream 'Buy' at You? They Don't for Me

The trouble for me, as an investor, is that this business remains in decline until it is not in decline.

Tough Tuesday, Wavering Consumer and Interpreting the Fed: Market Recon

Key to a China trade deal will be that both sides come away from the G-20 meeting with the feeling that progress has been made, and that the schedule of tariffs has not been expanded.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

2 Enigmatic Indices, Intriguing Oil, and Planet Fitness Slouches: Market Recon

Plus, a look at Ulta Beauty and a possible options play in the retailer.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight